Compare iShares Silver Trust (SLV) vs 10X Genomics Inc (TXG) Price & Performance

SLV, the iShares Silver Trust ETF, trades at $53.08, up 4.53% on the day, amid a broader precious metals rebound. Technical indicators are predominantly bearish, with moving averages signaling sell pressure, though short-term RSI suggests potential oversold conditions. Recent news highlights silver's sensitivity to interest rate expectations and geopolitical tensions, with supply deficits and industrial demand providing fundamental support. The ETF lacks traditional valuation metrics like P/E or P/B as it tracks physical silver.

The outlook for SLV hinges on macroeconomic factors, including Fed policy and silver's dual role as a monetary and industrial metal. Risks include persistent rate hikes and dollar strength, but long-term demand drivers offer appreciation potential. Investors should weigh silver's volatility against its hedge attributes.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.